Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes
NCT05597202
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
22
Enrollment
OTHER
Sponsor class
Conditions
Type 2 Diabetes
Interventions
DRUG:
Semaglutide, 2.0 mg/mL
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators
[object Object]